Rituxan plus Temodar Effective for Primary Central Nervous System Lymphoma
Researchers from Italy have reported that the combination of Rituxan (rituximab) and Temodar (temozolomide) is an effective treatment regimen for patients with primary central nervous system (CNS) non-Hodgkin’s lymphoma (NHL). This phase II study was presented at the 2005 meeting of the American Society of Clinical Oncology in Orlando, Florida, May 13-17 2005.
Primary central nervous system lymphoma is a relatively uncommon form of (NHL) that has been increasing in incidence over the past three decades. Unlike the progress made in general NHL treatment, there has been little progress in the treatment of CNS NHL. The standard treatment has been high-dose methotrexate and whole-brain radiotherapy. However, treatment-related neurotoxicity is common, especially in the elderly. Temodar is an alkylating agent used to treat primary and secondary brain tumors, especially glioblastoma multiforme.
More can be found in this article.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
